1 completed, 1 unknown, 1 withdrawn. 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
| Phase 4 | 1 | Completed 1 |
Follow Bivigam: new trials by email Literature Review of Bivigam trials Research Report on Bivigam
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Autologous Transplant To End NMO Spectrum Disorder Rituximab, Cyclophosphamide, Mesna - Neuromyelitis Optica, Devic's Disease | Phase 2 / Phase 3 | Withdrawn | Northwestern University | 2019-11-01 | 2019-11-20 | |
| Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16 Bivigam - Humoral Immune Response | Phase 4 | Completed | ADMA Biologics, Inc. | 16 | 2016-12-29 | 2023-02-01 |
| A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products Bivigam, Other - Primary Immune Deficiency Disorder | Unknown | ADMA Biologics, Inc. | 200 | 2016-12-01 | 2023-02-01 |
Neuromyelitis Optica (1) · Primary Immunodeficiency Diseases (1)
ADMA Biologics, Inc. (2) · Northwestern University (1)
United States (3)
Richard Burt, MD (1)